OS Therapies (NYSE: OSTX) details resale of 10,529,417 shares and legal opinion
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
OS Therapies Incorporated filed a prospectus supplement covering the resale of up to 10,529,417 shares of its common stock by certain selling stockholders. The supplement forms part of the company’s previously effective Form S-3 shelf registration statement. An accompanying Form 8-K provides counsel Olshan Frome Wolosky LLP’s legal opinion on the validity of these shares, filed as Exhibit 5.1, along with the related consent.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Resale registration size: 10,529,417 shares
1 metrics
Resale registration size
10,529,417 shares
Maximum common shares covered for resale in prospectus supplement
Key Terms
prospectus supplement, registration statement on Form S-3, resale, legal opinion, +1 more
5 terms
prospectus supplement regulatory
"filed with the U.S. Securities and Exchange Commission a prospectus supplement"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
registration statement on Form S-3 regulatory
"forms a part of the Company’s registration statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
resale financial
"covers the resale from time to time of up to 10,529,417 shares"
Resale is the act of selling an item, asset, or security by someone who previously bought it rather than by the original maker or issuer. It matters to investors because resale activity affects how easily an investment can be sold, the price buyers are willing to pay, and the potential profit or loss — like selling a used car: condition, demand and market rules determine what you can get for it.
legal opinion regulatory
"to provide the legal opinion of its counsel, Olshan Frome Wolosky LLP"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did OS Therapies Incorporated (OSTX) file on March 31, 2026?
OS Therapies Incorporated filed a Form 8-K and a prospectus supplement. The supplement is part of its Form S-3 shelf registration and addresses resale of common stock by selling stockholders.
What registration statement does the OS Therapies (OSTX) prospectus supplement relate to?
The prospectus supplement relates to OS Therapies’ registration statement on Form S-3, File No. 333-289443. That registration statement was filed on August 8, 2025 and declared effective on August 12, 2025.